“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in CHF
Last close As at 26/05/2023
CHF0.01
— 0.00 (−7.69%)
Market capitalisation
CHF16m
Based in Switzerland, Kinarus Therapeutics is a clinical-stage pharmaceutical company focused on advancing lead candidate KIN001 in inflammatory, fibrotic and/or viral infection-related conditions.
Upon availability of new funding, Kinarus plans to start a Phase II study in wet age-related macular degeneration, backed by preclinical data suggesting potential benefit in reducing choroidal neovascularisation lesions and in idiopathic pulmonary fibrosis. Having shown in vitro antiviral activity against many COVID-19 variants, KIN001 is currently being assessed in the KINFAST Phase II study in ambulatory COVID-19 patients.
Analyst - Healthcare
Dr. Alexander Bausch
CEO
Subhasis Roy
CFO
Forecast net debt (CHFm)
N/A
Forecast gearing ratio (%)
N/A
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | 26.5 | (21.5) | (82.3) |
| Relative | 26.3 | (23.1) | (82.3) |
| 52 week high/low | CHF0.1/CHF0.0 |
Kinarus has announced that it has entered into a CHF1.5m strategic convertible loan agreement with ChaoDian (Hangzhou) Investment Management, an investment company based in China. The CHF1.5m subordinated loan has a three-year fixed term and does not bear any interest, and is convertible to Kinarus shares at a fixed conversion price of CHF0.01 per share. In addition to supporting Kinarus’s financial position, the company indicates the loan agreement forms the basis for future discussions on the development and commercialisation of KIN001 for the treatment of idiopathic pulmonary fibrosis (IPF) in China. While discussions are preliminary and no deal or licensing arrangement can be assured at this stage, we are encouraged that KIN001 is attracting interest from potential partners and view this development as supportive of the underlying premise behind the potential anti-fibrotic and anti-inflammatory effects of KIN001.
| Y/E Dec | Revenue (CHFm) | EBITDA (CHFm) | PBT (CHFm) | EPS (fd) (CHFc) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2020A | 0.0 | (1.5) | (1.5) | (31.17) | N/A | N/A |
| 2021A | 0.0 | (5.1) | (4.9) | (0.41) | N/A | N/A |
| 2022E | N/A | N/A | N/A | N/A | N/A | N/A |
| 2023E | N/A | N/A | N/A | N/A | N/A | N/A |
Get access to the very latest content matched to your personal investment style.
